How to choose the right weight loss medication

The clinical decision framework

Choosing a weight loss medication is not like choosing a streaming service. You don't browse options, read reviews, and pick the one with the best marketing. The decision is clinical, collaborative, and constrained by insurance coverage rules.

At PEAK, we use a structured framework to determine which medication—if any—is appropriate for your situation:

Step 1: Establish medical necessity

Do you meet FDA criteria for GLP-1 therapy? This means BMI ≥30 (obesity) or BMI ≥27 (overweight) with at least one weight-related comorbidity like hypertension, type 2 diabetes, or dyslipidemia. If you don't meet these criteria, GLP-1 medications are not indicated—and insurance won't cover them.

Step 2: Rule out contraindications

Are there medical conditions that make GLP-1 therapy unsafe? This includes personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, history of severe pancreatitis, active gallbladder disease, or pregnancy. If any of these apply, GLP-1 medications are not an option.

Step 3: Assess which GLP-1 medications your insurance covers

Your insurance plan's formulary determines which medications are accessible. Most plans cover either Wegovy or Zepbound for weight loss (with prior authorization), but rarely both. If your plan covers Wegovy, that's your starting point. If it covers Zepbound, that's your option. If it covers neither, we discuss cash-pay alternatives or appeal strategies.

Step 4: Consider comorbidities and clinical fit

If you have type 2 diabetes, your clinician may recommend a GLP-1 approved for diabetes (Ozempic or Mounjaro) rather than a weight-loss-specific formulation, depending on which condition is the primary treatment target. If you have cardiovascular disease, medications with proven cardiovascular benefits (like semaglutide) may be prioritized.

Step 5: Evaluate side effect tolerance and patient preference

All GLP-1 medications cause gastrointestinal side effects in some patients—nausea, reduced appetite, occasional vomiting. If you've tried a GLP-1 before and couldn't tolerate it, your clinician may suggest a different formulation or a slower titration schedule. Patient preference matters, but it's informed by clinical guidance.

Medical factors that matter

Here are the clinical factors your PEAK clinician considers when recommending a specific GLP-1 medication:

If you have type 2 diabetes

Your clinician may recommend Ozempic (semaglutide) or Mounjaro (tirzepatide), both of which are FDA-approved for diabetes management and produce significant weight loss as a secondary benefit. Alternatively, they may recommend Wegovy or Zepbound if weight loss is the primary treatment goal and you meet the criteria for chronic weight management.

If you have cardiovascular disease

Semaglutide (Wegovy/Ozempic) has demonstrated cardiovascular risk reduction in clinical trials. If you have established cardiovascular disease, your clinician may prioritize semaglutide-based therapy over tirzepatide, though tirzepatide trials are ongoing.

If you've tried semaglutide and plateaued

Some patients reach a weight loss plateau on semaglutide and benefit from switching to tirzepatide (Zepbound), which has a dual GIP/GLP-1 mechanism. Head-to-head trials show tirzepatide produces modestly greater average weight loss than semaglutide, though individual responses vary.

If you have a history of gastroparesis or severe GI issues

GLP-1 medications slow gastric emptying, which can worsen gastroparesis. If you have significant GI motility disorders, your clinician may determine GLP-1 therapy is not appropriate, or they may start at a very low dose and titrate extremely slowly.

If you're planning pregnancy

GLP-1 medications must be discontinued at least 2 months before conception. If you're planning to become pregnant in the near term, your clinician will discuss whether starting GLP-1 therapy makes sense or whether other approaches are more appropriate.

Insurance coverage considerations

This is the part patients find frustrating: the "best" medication is often the one your insurance actually covers.

Most commercial insurance plans that cover weight loss medications will cover either Wegovy or Zepbound, but not both. Medicare currently does not cover GLP-1 medications for weight loss (though it covers them for diabetes). Medicaid coverage varies by state.

If your plan covers Wegovy with prior authorization, that becomes your primary option—even if clinical trials suggest tirzepatide might produce slightly greater weight loss. If your plan covers Zepbound, that's your path forward.

At PEAK, we verify your coverage before prescribing. We do not prescribe a medication and then leave you to figure out how to pay for it. We check your formulary, submit prior authorization, and only move forward once we know your coverage status.

Comparing your incretin-based medication options

Here's a simplified comparison of the FDA-approved incretin-based medications most commonly prescribed for weight management:

Wegovy (semaglutide, 2.4 mg weekly)

• FDA approval: Chronic weight management
• Average weight loss: Approximately 15% of body weight (14.9% in the STEP 1 trial) over 68 weeks
• Mechanism: GLP-1 receptor agonist
• Cardiovascular benefit: Proven risk reduction in patients with established CVD
• Common side effects: Nausea, reduced appetite, constipation
• Typical insurance coverage: Covered by many plans with prior authorization

Zepbound (tirzepatide, up to 15 mg weekly)

• FDA approval: Chronic weight management
• Average weight loss: up to 22.5% of body weight at 15 mg (SURMOUNT-1, 72 weeks)
• Mechanism: Dual GIP/GLP-1 receptor agonist
• Cardiovascular benefit: Under investigation; preliminary data positive
• Common side effects: Nausea, diarrhea, reduced appetite
• Typical insurance coverage: Covered by many plans with prior authorization

Saxenda (liraglutide, 3.0 mg daily)

• FDA approval: Chronic weight management
• Average weight loss: approximately 8% of body weight over 56 weeks
• Mechanism: GLP-1 receptor agonist (daily injection)
• Common side effects: Nausea, headache, hypoglycemia in diabetic patients
• Typical insurance coverage: Less commonly covered; often requires step therapy

Note: Ozempic and Mounjaro are also semaglutide and tirzepatide, respectively, but they are FDA-approved for diabetes, not weight loss. They may be prescribed off-label for weight management in patients without diabetes, but insurance typically will not cover this use.

How PEAK approaches this decision

At PEAK, medication selection is a conversation, not a prescription pad transaction. Here's how it works:

Your first visit: Your clinician reviews your health history, conducts a physical exam, orders baseline labs, and discusses your goals. Based on this evaluation, they determine whether you're a candidate for GLP-1 therapy.

Insurance verification: Before prescribing, we verify your insurance coverage and identify which medications your plan covers. We handle prior authorization submission and keep you informed about approval status.

Medication recommendation: Your clinician recommends a specific medication based on your comorbidities, insurance coverage, and clinical fit. They explain why that medication makes sense for your situation and answer your questions.

Ongoing monitoring: Once you start treatment, you return for follow-up visits every 4–6 weeks. Your clinician tracks your response, adjusts your dose, manages side effects, and determines whether the medication is working. If it's not, we adjust the plan—whether that means switching medications, modifying your dose, or exploring other approaches.

This is not a one-size-fits-all process. It's individualized medicine built around your health, your insurance, and your goals.

What to expect next

If you're ready to explore GLP-1 therapy, the next step is a consultation. That means:

• Submitting your information online
• Insurance verification by our team within one business day
• A scheduled in-person visit at our Chesapeake office
• Face-to-face evaluation with a clinician who will determine candidacy and recommend a medication

We don't prescribe based on a questionnaire. We prescribe based on clinical evaluation. If you're a candidate, we handle the insurance authorization process and walk you through what to expect from treatment. If you're not a candidate, we tell you honestly—and we discuss alternatives.

The PEAK Clinical Team

PEAK Wellness & Aesthetics

Evidence-based guidance from our board-certified clinicians specializing in medical weight loss and obesity medicine.